-
Media Release
Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population
-
Media Release
Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN)
-
Media Release
Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
-
Media Release
Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US
-
Media Release
New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies
-
Story
How Social Workers Can Make a Difference for Advanced Prostate Cancer Patients -
Story
Novartis in San Diego: A Quarter Century of R&D Innovation -
Story
Designing for the Future: The Next Era of Biomedical Research in San Diego -
Media Release
Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure
-
Media Release
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease
-
Media Release
Novartis twice-yearly* Leqvio® (inclisiran) receives FDA approval for new indication enabling first-line use
-
Media Release
Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)